Follows adults with chronic lymphocytic leukemia treated with venetoclax in routine care
Observes how venetoclax, alone or combined, works in adults with leukemia.
Plain-language title generated from the registry record
Registry title: Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Key facts
- Where
- Graz, Salzburg, Sankt Pölten, and Vienna, AustriaSee the 4 sites
Where in Austria
- Medizinische Universitaet Graz /ID# 221155Graz, AustriaNo longer taking part
- Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153Salzburg, AustriaNo longer taking part
- Universitaetsklinikum St. Poelten /ID# 221152Sankt Pölten, AustriaNo longer taking part
- Hanusch Krankenhaus /ID# 221151Vienna, AustriaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT03342144
- Record updated
- 21 October 2026
- Original description
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.Read full original descriptionShow less
Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
Inclusion: Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.
Exclusion: None.